scholarly journals Mandate for creation of a national peripheral arterial disease public awareness program: an opportunity to improve cardiovascular health

2004 ◽  
Vol 39 (2) ◽  
pp. 474-481 ◽  
Author(s):  
Alan T. Hirsch ◽  
Peter Gloviczki ◽  
Alain Drooz ◽  
Marge Lovell ◽  
Mark A. Creager
Keyword(s):  
Peripheral Arterial Disease ◽  
Cardiovascular Health ◽  
Public Awareness ◽  
Arterial Disease ◽  
Awareness Program ◽  
Peripheral Arterial ◽  
Public Awareness Program

Mandate for Creation of a National Peripheral Arterial Disease Public Awareness Program: An Opportunity to Improve Cardiovascular Health

Angiology ◽  
2004 ◽  
Vol 55 (3) ◽  
pp. 233-242 ◽  
Author(s):  
Alan T. Hirsch ◽  
Peter Gloviczki ◽  
Alain Drooz ◽  
Marge Lovell ◽  
Mark A. Creager ◽  
...  
Keyword(s):  
Peripheral Arterial Disease ◽  
Cardiovascular Health ◽  
Public Awareness ◽  
Arterial Disease ◽  
Awareness Program ◽  
Peripheral Arterial ◽  
Public Awareness Program

scholarly journals Symptoms of Intermittent Claudication and Decreased Walking Tolerance in Patients Suffering from Peripheral Arterial Disease can be Improved with a Simple Herbal Supplement

2020 ◽  
pp. 1-5
Author(s):  
Ping-Chung Leung ◽  
Chook Ping ◽  
Kwok Chi Yui Timothy ◽  
Ping-Chung Leung ◽  
Woo Kam Sang ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Placebo Group ◽  
Treatment Group ◽  
Peripheral Arterial Disease ◽  
Cardiovascular Health ◽  
Arterial Disease ◽  
Walking Distance ◽  
Care Practice ◽  
Pragmatic Clinical Trials ◽  
Peripheral Arterial

Introduction: We have developed an innovative herbal formula containing two herbs of popular use for the supplementation of cardiovascular health. Three clinical trials, viz. on patients with coronary arterial obstruction, hypertension, and post-menopausal borderline hyperlipidaemia, have been done, all showing promising results detected in ultrasonography as diminished intima media thickness (IMT), a surrogate marker recommended for clinical trials related to cardiovascular health. 49+49 patients with known peripheral arterial disease (PAD) were treated with twin formula or placebo group for 24 weeks. Assessment using ultrasonography showed thinning down of the carotid intima (2.67%) only in the treatment group. Maximal walking distance also increased by 21.8% in the treatment group compared with 7.2% in the placebo group (p=0.499). Discussion: The positive results in the PAD study as well as in the other studies done previously demonstrated the effectiveness of the twin formula in the maintenance of cardiovascular health. It is safe and offers direct protection of the internal environment of the artery while at the same time carries the multiple roles of anti-inflammation, anti-oxygenation and anti-fibrosis, as were shown in in vitro and animal bioactivity studies. Conclusion and Outlook: The twin formula offers a good example of evidence-based medicinal supplements with specific functions. Its developmental process also offers a more comprehensive way to test traditional wisdom and practice through pragmatic clinical trials in the attempt to properly introduce it to modern health care practice.

scholarly journals Primary care screening for peripheral arterial disease: a cross-sectional observational study

2017 ◽  
Vol 67 (655) ◽  
pp. e103-e110 ◽  
Author(s):  
Jane H Davies ◽  
Jonathan Richards ◽  
Kevin Conway ◽  
Joyce E Kenkre ◽  
Jane EA Lewis ◽  
...  
Keyword(s):  
Primary Care ◽  
Observational Study ◽  
Peripheral Arterial Disease ◽  
Public Awareness ◽  
Ankle Brachial Index ◽  
Arterial Disease ◽  
Smoking History ◽  
Cross Sectional ◽  
Number Needed To Screen ◽  
Peripheral Arterial

BackgroundEarly identification of peripheral arterial disease (PAD) and subsequent instigation of risk modification strategies could minimise disease progression and reduce overall risk of cardiovascular (CV) mortality. However, the feasibility and value of primary care PAD screening is uncertain.AimThis study (the PIPETTE study — Peripheral arterial disease In Primary carE: Targeted screening and subsequenT managEment) aimed to determine the value of a proposed primary care PAD screening strategy. Outcomes assessed were: prevalence of PAD and agreement of ankle– brachial index (ABI)-defined PAD (ABI ≤0.9) with QRISK®2-defined high CV risk (≥20).Design and settingA cross-sectional observational study was undertaken in a large general practice in Merthyr Tydfil, Wales.MethodIn total, 1101 individuals with ≥2 pre-identified CV risk factors but no known CV disease or diabetes were invited to participate. Participants underwent ABI measurement and QRISK2 assessment, and completed Edinburgh Claudication Questionnaires.ResultsA total of 368 people participated in the study (participation rate: 33%). Prevalence of PAD was 3% (n = 12). The number needed to screen (NNS) to detect one new case of PAD was 31. Refining the study population to those aged ≥50 years with a smoking history reduced the NNS to 14, while still identifying 100% of PAD cases. Of participants with PAD, 33% reported severe lifestyle-limiting symptoms of intermittent claudication that warranted subsequent endovascular intervention, yet had not previously presented to their GP. The QRISK2 score predicted high CV risk in 92% of participants with PAD.ConclusionThe low PAD yield and the fact that QRISK2 was largely comparable to the ABI in predicting high CV risk suggests that routine PAD screening may be unwarranted. Instead, strategies to improve public awareness of PAD are needed.

Sign in / Sign up

Export Citation Format

Share Document